Literature DB >> 27619390

Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Alyce J M Anderson1, Benjamin Click2, Claudia Ramos-Rivers2, Dmitriy Babichenko3, Ioannis E Koutroubakis2, Douglas J Hartman4, Jana G Hashash2, Marc Schwartz2, Jason Swoger2, Arthur M Barrie2, Michael A Dunn2, Miguel Regueiro2, David G Binion5.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a heterogeneous collection of chronic inflammatory disorders of the digestive tract. Clinical, genetic, and pathological heterogeneity makes it increasingly difficult to translate efficacy studies into real-world practice. Our objective was to develop a comprehensive natural history registry derived from multi-year observational data to facilitate effectiveness and clinical phenotypic research in IBD.
METHODS: A longitudinal, consented registry with prospectively collected data was developed at UPMC. All adult IBD patients receiving care at the tertiary care center of UPMC are eligible for enrollment. Detailed data in the electronic health record are accessible for registry research purposes. Data are exported directly from the electronic health record and temporally organized for research.
RESULTS: To date, there are over 2565 patients participating in the IBD research registry. All patients have demographic data, clinical disease characteristics, and disease course data including healthcare utilization, laboratory values, health-related questionnaires quantifying disease activity and quality of life, and analytical information on treatment, temporally organized for 6 years (2009-2015). The data have resulted in a detailed definition of clinical phenotypes suitable for association studies with parameters of disease outcomes and treatment response. We have established the infrastructure required to examine the effectiveness of treatment and disease course in the real-world setting of IBD.
CONCLUSIONS: The IBD research registry offers a unique opportunity to investigate clinical research questions regarding the natural course of the disease, phenotype association studies, effectiveness of treatment, and quality of care research.

Entities:  

Keywords:  Inflammatory bowel disease; Natural history; Phenotyping; Registry

Mesh:

Year:  2016        PMID: 27619390      PMCID: PMC5069178          DOI: 10.1007/s10620-016-4278-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

1.  Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study.

Authors:  Jana G Hashash; Preethi Chintamaneni; Claudia M Ramos Rivers; Ioannis E Koutroubakis; Miguel D Regueiro; Leonard Baidoo; Jason M Swoger; Arthur Barrie; Marc Schwartz; Michael A Dunn; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

2.  A multiregional registry experience using an electronic medical record to optimize data capture for longitudinal outcomes in endovascular abdominal aortic aneurysm repair.

Authors:  Robert J Hye; Tazo S Inui; Faith F Anthony; Mary-Lou Kiley; Robert W Chang; Thomas F Rehring; Nicolas A Nelken; Bradley B Hill
Journal:  J Vasc Surg       Date:  2015-02-26       Impact factor: 4.268

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

5.  Predictors and risks for death in a population-based study of persons with IBD in Manitoba.

Authors:  Charles N Bernstein; Zoann Nugent; Laura E Targownik; Harminder Singh; Lisa M Lix
Journal:  Gut       Date:  2014-09-16       Impact factor: 23.059

6.  Long-term durability of response to adalimumab in Crohn's disease.

Authors:  M Chaparro; J Panés; V García; O Merino; P Nos; E Domènech; M Peñalva; E García-Planella; M Esteve; J Hinojosa; M Andreu; F Muñoz; A Gutiérrez; J L Mendoza; J Barrio; M Barreiro-de; I Vera; P Vilar; J L Cabriada; M A Montoro; X Aldeguer; C Saro; J P Gisbert
Journal:  Inflamm Bowel Dis       Date:  2011-05-25       Impact factor: 5.325

7.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

8.  Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study.

Authors:  Toufic A Kabbani; Ioannis E Koutroubakis; Robert E Schoen; Claudia Ramos-Rivers; Nilesh Shah; Jason Swoger; Miguel Regueiro; Arthur Barrie; Marc Schwartz; Jana G Hashash; Leonard Baidoo; Michael A Dunn; David G Binion
Journal:  Am J Gastroenterol       Date:  2016-03-08       Impact factor: 10.864

9.  Durability of infliximab in Crohn's disease: a single-center experience.

Authors:  Jason E Gonzaga; Ashwin N Ananthakrishnan; Mazen Issa; Dawn B Beaulieu; Sue Skaros; Yelena Zadvornova; Kathryn Johnson; Mary F Otterson; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05-21       Impact factor: 5.325

10.  Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization.

Authors:  Benjamin Click; Eric J Vargas; Alyce M Anderson; Siobhan Proksell; Ioannis E Koutroubakis; Claudia Ramos Rivers; Jana G Hashash; Miguel Regueiro; Andrew Watson; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

View more
  8 in total

1.  Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease: A Propensity Score Matched Analysis.

Authors:  Alyce Anderson; Benjamin Click; Claudia Ramos-Rivers; Debbie Cheng; Dmitriy Babichenko; Ioannis E Koutroubakis; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2017-12       Impact factor: 5.325

2.  Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance and Healthcare Utilization in Patients with Inflammatory Bowel Disease.

Authors:  Sumedha V Chablani; Claudia Ramos-Rivers; David G Binion; Eva Szigethy
Journal:  Dig Dis Sci       Date:  2018-07-19       Impact factor: 3.199

3.  Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.

Authors:  Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Dmitriy Babichenko; Jorge D Machicado; Douglas J Hartman; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Sally E Wenzel; Miguel Regueiro; David G Binion
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

4.  Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients.

Authors:  Alyce Anderson; Laura K Ferris; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Michael Dunn; Arthur Barrie; Marc Schwartz; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2018-04-30       Impact factor: 3.199

Review 5.  Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions.

Authors:  John Gubatan; Steven Levitte; Akshar Patel; Tatiana Balabanis; Mike T Wei; Sidhartha R Sinha
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

6.  Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.

Authors:  Alyce Anderson; Cynthia Cherfane; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Dmitriy Babichenko; Gong Tang; Michael Dunn; Arthur Barrie; Siobhan Proksell; Jeffrey Dueker; Elyse Johnston; Marc Schwartz; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2022-01-05       Impact factor: 5.325

7.  A Methodology to Generate Longitudinally Updated Acute-On-Chronic Liver Failure Prognostication Scores From Electronic Health Record Data.

Authors:  Jin Ge; Nader Najafi; Wendi Zhao; Ma Somsouk; Margaret Fang; Jennifer C Lai
Journal:  Hepatol Commun       Date:  2021-03-12

8.  The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease.

Authors:  Alyce Anderson; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2018-06-08       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.